A recent study indicates that individuals who discontinue new weight-loss injections like Mounjaro or Wegovy can put back on shed pounds far faster than those who halt conventional diet and exercise programs.
Findings released in a prominent health publication shows that while overweight people often shed substantial amounts of their total mass while using the jabs, the weight returns at an average rate of nearly a kilo each month upon discontinuation.
"Users buying these medications should be cognizant of the risk of quick weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to original weight within about 18 months.
Weighing Approaches
The research, which reviewed dozens of studies involving thousands of patients, contrasted the results of these new drugs with other pills.
Researchers note that individuals who lose weight through lifestyle changes alone typically see a slower creep back—approximately 100 grams monthly—once they finish.
Understanding the Rapid Regain
Nutrition scientists propose the mechanism of the injections is key to understanding the heightened weight return.
The injections copy a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Condition?
Medical guidelines suggest the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, given the likelihood of relapse, the therapy should be considered life-long.
This view is echoed by pharmaceutical companies, who say that the findings "emphasize the long-term character of excess weight," comparing it to managing diseases like hypertension.
User Experiences
Users who have discontinued the jabs explain a powerful resurgence of hunger.
"I experienced a switch flipping and I was suddenly starving," described an individual.
This challenge is compounded if users have not adopted lasting dietary or behavioural changes during therapy.
Widespread Adoption
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Adoption is higher among females than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are potent agents for weight loss, they are not a magic cure and long-term success likely depends on combined behavioural management.
